|
 
 |
| CASE REPORT |
|
| Year : 2023 | Volume
: 3
| Issue : 1 | Page : 7 |
|
COVID–19 breakthrough infection after four doses of the vaccines: A case report
Hongrang Zhou1, Guifu Li1, Xiaoming Wang2, Zhe Zhou1, Wen Kong1, Jingfei Hu1, Kaiyou Ye1, Wenjiang Zhong1, Xiaoling Wang3, Ning Xiao4
1 Qingpu District Center for Disease Control and Prevention, Shanghai 201799, China
2 Program in Public Health, College of Health Sciences, University of California at Irvine, Irvine 92697, USA
3 State Key Laboratory of Genetic Engineering, Ministry of Education Key Laboratory of Contemporary Anthropology, Department of Microbiology and Microbial Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China
4 National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention; Chinese Center for Tropical Diseases Research; WHO Collaborating Centre for Tropical Diseases; National Center for International Research on Tropical Diseases, Ministry of Science and Technology; Key Laboratory of Parasitic and Vector Biology, National Health Commission of China; The School of Global Health, Chinese Center for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China
| Date of Submission | 13-Feb-2023 |
| Date of Decision | 13-Mar-2023 |
| Date of Acceptance | 26-Mar-2023 |
| Date of Web Publication | 20-Apr-2023 |
Correspondence Address:
Hongrang Zhou
Qingpu District Center for Disease Control and Prevention, Shanghai 201799
China
Ning Xiao
National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention; Chinese Center for Tropical Diseases Research; WHO Collaborating Centre for Tropical Diseases; National Center for International Research on Tropical Diseases, Ministry of Science and Technology; Key Laboratory of Parasitic and Vector Biology, National Health Commission of China; The School of Global Health, Chinese Center for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai 200001
China
Wenjiang Zhong
Qingpu District Center for Disease Control and Prevention, Shanghai 201799
China
Xiaoling Wang
State Key Laboratory of Genetic Engineering, Ministry of Education Key Laboratory of Contemporary Anthropology, Department of Microbiology and Microbial Engineering, School of Life Sciences, Fudan University, Shanghai 200433
China
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/2773-0344.374229
The COVID-19 vaccines provide a high degree of protection against severe disease, hospitalisation, and death. However, no vaccine claimed 100% effectiveness and it is expected that a small proportion of vaccinated individuals may develop a breakthrough infection due to individual differences, virus variants and other factors. We conducted an epidemiological investigation and analysis of an imported case who had finished four doses of vaccination, and in order to provide a relevant reference for regular epidemic prevention and control in the post-pandemic era. Keywords: Breakthrough infection; COVID-19; Vaccination
How to cite this article:
Zhou H, Li G, Wang X, Zhou Z, Kong W, Hu J, Ye K, Zhong W, Wang X, Xiao N. COVID–19 breakthrough infection after four doses of the vaccines: A case report. One Health Bull 2023;3:7 |
How to cite this URL:
Zhou H, Li G, Wang X, Zhou Z, Kong W, Hu J, Ye K, Zhong W, Wang X, Xiao N. COVID–19 breakthrough infection after four doses of the vaccines: A case report. One Health Bull [serial online] 2023 [cited 2023 May 31];3:7. Available from: http://www.johb.info/text.asp?2023/3/1/7/374229 |
| 1. Introduction | |  |
Since the outbreak of Coronavirus Disease 2019 (COVID-19), countries around the world have adopted different ways to contain the spread of the coronavirus. Vaccination is the most cost-efficient and effective strategy for preventing infectious diseases[1],[2]. In response to the COVID-19 pandemic, many countries have accelerated vaccination efforts and rapidly built up immunity barrier for the entire population during the COVID-19 pandemic. However, vaccines are not 100% effective[3], meaning COVID-19 breakthrough infection after vaccination are possible. As the epidemic spread, breakthrough infections related to a series of factors including virus variation, transmissibility, pathogenicity immune evasion and health disparities of individual become more frequent. This study introduced a case of COVID-19 infection who had received four doses of the vaccine, which may serve as a benchmark for future studies.
| 2. Case report | | |
A 32-year-old male returning from the Democratic Republic of the Congo (DR Congo) tested positive reverse transcription polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) under medical observation at a designated isolation location by Qingpu Center for Disease Control and Prevention (CDC), Shanghai, China, December 31, 2021. Two colleagues who traveled with him tested negative. According to the patient’s self-description, he worked as a cost of engineering in a company in Lubumbashi City, DR Congo from March 15 to December 21, 2021 and was in good health without the history of smoking, alcohol consumption, diabetes mellitus, or hypertension.
The case’s epidemiological investigation revealed that the patient received two doses of COVID-19 vaccine (Sinovac Research & Development Co. LTD) on February 21 and March 9, 2021 in a hospital in Beijing, China (Beijing time). The case then flew to work in Lubumbashi, DR Congo on March 15, 2021 and received two further doses of the COVID-19 vaccine (Beijing Institute of Biological Products Co. LTD) in a hospital in Lubumbashi, DR Congo on July 30 and August 25, 2021 (Local time). [Figure 1] shows the COVID-19 vaccination and travel history. | Figure 1: The patient's COVID-19 vaccination record and the travel history from February 21 to December 31, 2021.
Click here to view |
The case began self-isolation at home in Lubumbashi City, DR Congo from December 1 to 21, 2021, before returning to China. He and his two coworkers visited the nearby hospital for nucleic acid testing three times on December 8, 18 and 20, 2021, respectively. On December 22, 2021, they flew to Addis Ababa, Ethiopia from Lubumbashi City, DR Congo, and the case spent 1.5 h to pick up the checked baggage. The three were subsequently quarantined for seven days at a hotel close to the airport, where they stayed there the entire time. And the medical staff took nucleic acid test samples in the hotel room on December 23, 26, and 27, 2021, respectively. On December 28, 2021, the case returned from Addis Abeba, Ethiopia, to Shanghai Pudong, China, where he spent 0.5 h retrieving the checked baggage. He was subsequently transported by airport bus to a Shanghai quarantine point in Qingpu District, where he was placed under medical observation there for 14 days.
During the case’s self isolation at home in Lubumbashi City, DR Congo, and the seven-day quarantine at the hotel in Addis Ababa, Ethiopia, as well as at the airport of Shanghai Pudong, a series of antibody and nucleic acid tests were performed. However, on December 31, 2021, the fourth day of quarantine in Qingpu District, Shanghai, the case got a positive PCR result for coronavirus. On the same day, the patient presented with mild cold and sputum in the throat. The results of related laboratory tests in the assigned hospital showed that the white blood cell count was 7.35×109/L, the lymphocyte was 0.94×109/L, and the lung CT showed a little chronic inflammation in the left lower lobe. On January 1, 2022, freshly obtained samples from the case were retested by the Shanghai Municipal Center for Disease Control and Prevention. With the exception of Immunoglobulin M (IgM), all other tests were positive, including nasal swabs, throat swabs, sputum and anal swabs for COVID-19 nucleic acid detection and the serum Immunoglobulin G (IgG). The specific antibody and nucleic acid test results are shown in [Figure 2]. | Figure 2: The serum antibody test results of the patient and his two colleagues in Congo, Ethiopia and China. #The result of nucleic acid test; * The nucleic acid test results for the case on December 31, 2021; ^ The nucleic acid test results for the two colleagues on December 31, 2021.
Click here to view |
As soon as the information confirmed, the case was reported to the Shanghai CDC immediately and the appropriate treatment measures were also actively performed. According to the guidelines and procedures for identifying and monitoring the close contacts developed by the China CDC, the patient’s close contacts were screened quickly by the Shanghai CDC and the corresponding medical isolation and control measures were taken.
| 3. Discussion | | |
The current evidence indicates that in fully vaccinated people the risk of SARS-CoV-2 infection hospitalization, severe illness, and death from COVID-19 is relatively less. However, the risk of breakthrough infection in fully vaccinated people can’t be eliminated due to the individual differences, COVID-19 variant strains and other factors[4],[5],[6],[7].
The case in this study have received the fourth dose of COVID-19 vaccination and had protective antibodies (such as IgG) in his body, but he was still infected. Until the patient recovered and discharged from the hospital and completed another 14 days of isolation, no one at the company where the case worked tested positive and the two colleagues on the same trip were also not infected. The case spent the entire time in the company and home except for nucleic acid testing during the home isolation period in DR Congo. The itineraries of the case, coworkers A and B were basically the same, and the seats on the two flights were adjacent (except for drinking and eating, the three wore the same N95 masks throughout the whole trips). The case did not stayed with coworkers A and B during the baggage claim at the Addis Ababa Bole International Airport (Ethiopia) and Pudong International Airport (China), as well as during the isolation period in the Ethiopia hotel. Combining the case' itinerary and the IgM test results of the case and two colleagues in each period, it is inferred that the case was probably to be infected with COVID-19 during the travel (especially at the baggage claim area), and the possibility of cross-infection due to nucleic acid sampling during the three isolation periods in Congo, Ethiopia (it is uncertain whether the hotel had confirmed cases of COVID-19 when the case was quarantined) and Shanghai (even though there were no additional positive cases in the hotel when the patient was quarantined) cannot be ruled out.
Currently, certain nations and areas have begun administering the fourth dose of COVID-19 vaccine[8],[9]. However, a study by Israel’s Sheba Medical Center has discovered that while the fourth dose of the COVID-19 vaccine increases antibodies to levels even higher than the third shot, it is insufficient to prevent Omicron infections[10]. It is advised that even after the initial immunization and booster shot, fully vaccinated people must remain vigilant in adhering to the non pharmaceutical interventions, such as wearing a mask in public and indoor settings to prevent and control SARS-CoV-2 transmission in the community.
Conflict of interest statement
The authors declare that there is no conflict of interest.
Funding
The study received no extramural funding.
Authors’ contributions
Zhou HR and Zhong WJ designed the study. Zhou HR, Zhou Z, Kong W and Hu JF conducted the epidemiological investigation and collected the materials. Zhou HR and Wang XL analyzed the data and drafted the initial manuscript. Li GF, Wang XM, and Ye KY contributed to the critical revision of the article. Zhou HR, Zhong WJ, Wang XL and Xiao N reviewed and edited the content of the whole paper. All authors reviewed subsequent drafts of the manuscript and approved the final version.
Publisher’ s note
The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
| References | | |
| 1. | Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q. Progress and prospects on vaccine development against SARS-CoV-2. Vaccines 2020; 8(2):153. doi: 10.3390/vaccines8020153.  |
| 2. | Li J, Gao L, Li XY, Li YG, Wang FS. COVID-19 vaccines primary features and research progress on possible trigger of liver injury post-vaccination. Zhonghua Gan Zang Bing Za Zhi 2022; 30(5): 554-558. (In Chinese). |
| 3. | |
| 4. | Ma C, Xu S, Yao Y, Yu P, Xu Y, Wu R, et al. Mild breakthrough infection in a healthcare professional working in the isolation area of a hospital designated for treating COVID-19 patients—Shaanxi province, China, March, 2021. China CDC Weekly 2021; 3(19): 397-400. |
| 5. | Zhou H, Wang X, Li G, Wang S, Wang X, Wang Y, et al. An imported confirmed case of COVID-19 vaccinated in Brazil—Shanghai municipality, China, March 17, 2021. China CDC Weekly 2021; 3(30): 650. |
| 6. | Gao B, He LH, Bao YJ, Chen YY, Lu GZ, Zhang Y, et al. Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection. Cell Res 2023; 33: 258–261. doi: 10.1038/s41422-023-00781-8. |
| 7. | Fadlyana E, Setiabudi D, Kartasasmita CB, Putri ND, Rezeki Hadinegoro S, Mulholland K; BCOV21 study group. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: A randomised, observer-masked, controlled trial in Indonesia. Lancet Infect Dis 2023; 11: S1473-3099 (22)00800-3. doi: 10.1016/S1473-3099 (22)00800-3. |
| 8. | Alejo JL, Mitchell J, Chiang TP, Abedon AT, Boyarsky BJ, Avery RK, et al. Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: A case series. Transplantation 2021; 105(12): e280-e281. |
| 9. | Burki TK. Fourth dose of COVID-19 vaccines in Israel. Lancet Respir Med 2022; 10(2): e19. |
| 10. | Cohen MJ, Oster Y, Moses AE, Spitzer A, Benenson S; Israeli-Hospitals 4th Vaccine Working Group. Association of receiving a fourth dose of the BNT162b vaccine with SARS-CoV-2 infection among health care workers in Israel. JAMA Netw Open 2022; 5(8): e2224657. |
[Figure 1], [Figure 2]
|
Search Pubmed for